Cryoport announced it will provide its cold chain logistics solutions to support Nohla Therapeutics' clinical studies evaluating its universal donor cell therapy, NLA101, in patients with hematologic malignancies and other critical diseases. Cryoport's solutions help companies increase their ability to supply product for clinical trials.
As a part of the agreement, Cryoport will provide global logistics support for Nohla's Phase 2 clinical trials, observing international best practices for transporting cryogenically preserved commodities. Cryoport's suite of unique cryogenic logistics solutions includes its Cryoport Express shippers, SmartPak II Condition Monitoring System, Cryoportal Logistics Management Platform and 24/7/365 logistics support. These unparalleled capabilities enable Nohla to monitor its shipments and track the conditions and location of its biological commodities in transit around the clock, and to deploy intervention capability to mitigate any potential logistics risks.
"Umbilical cord blood is known to be a useful source for blood stem cells and has been used to treat patients with certain blood diseases,” Jerrell Shelton, Chief Executive Officer of Cryoport said. “Nohla Therapeutics is pioneering new universal donor off-the-shelf cord blood therapies designed to save lives, with a focus on individuals with hematologic malignancies, and we are proud that Nohla has selected Cryoport's advanced temperature controlled logistics solutions to support delivery of NLA101 to clinical trial sites. We look forward to working with Nohla and providing global logistics solutions."
Nohla is a developer of universal donor cell therapies for patients with hematologic malignances and other critical diseases. NLA101, the first product from Nohla's technology platform, is a regenerative cell therapy consisting of ex vivo expanded stem and progenitor cells derived from umbilical cord blood, available off the shelf without the need for HLA matching to the recipient. A randomized Phase 2 study is currently ongoing evaluating NLA101 in patients receiving a cord blood transplant. Nohla is also initiating a second randomized Phase 2 study evaluating NLA101 in acute myeloid leukemia (AML) patients at risk for myelosuppression following high-dose chemotherapy.